[盐酸吉西他滨治疗胰腺癌的结果]
[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].
作者信息
Tsukagoshi S
机构信息
Cancer Institute, Japan Foundation Cancer Research.
出版信息
Gan To Kagaku Ryoho. 2001 Oct;28(10):1461-7.
Pancreatic cancer has extremely poor prognosis. However no satisfactory effective chemotherapy for this cancer has been established. Gemcitabine hydrochloride, a novel anti-tumor agent, had shown the remarkable clinical efficacy for pancreatic cancer. In April 2001, the indication for pancreatic cancer of this agent has been approved in Japan and it is expected to be widely and increasingly introduced for clinical use. This review summarizes the study results of gemcitabine mono-therapy for pancreatic cancer and discusses other possibility of the treatment by Gemcitabine with the reported data about its combination therapy with other anti-cancer drug or radiation.
胰腺癌的预后极差。然而，针对这种癌症尚未确立令人满意的有效化疗方法。新型抗肿瘤药物盐酸吉西他滨已显示出对胰腺癌具有显著的临床疗效。2001年4月，该药物用于胰腺癌的适应证在日本获得批准，预计将被广泛且越来越多地引入临床使用。本文综述了吉西他滨单药治疗胰腺癌的研究结果，并结合其与其他抗癌药物联合治疗或放疗的报道数据，探讨了吉西他滨治疗的其他可能性。
Zotero 插件